Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

J Immunother Cancer 2016 16;4:50. Epub 2016 Aug 16.

University of Chicago Comprehensive Cancer Center and Pathology, Chicago, IL USA.

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0152-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986340PMC
August 2016
27 Reads

Publication Analysis

Top Keywords

immune-checkpoint blocking
12
blocking antibodies
12
cardiotoxicity ipilimumab
4
ipilimumab and/or
4
immune-related cardiotoxicity
4
administration immune-checkpoint
4
antibodies cases
4
cases immune-related
4
and/or nivolumab/pembrolizumab
4
nivolumab/pembrolizumab identified
4
reported large
4
large variety
4
variety cardiotoxic
4
follow-up reported
4
treatment follow-up
4
identified diagnostic
4
diagnostic findings
4
findings treatment
4
experience administration
4
centers substantial
4

References

(Supplied by CrossRef)

FS Hodi et al.
N Engl J Med 2010

C Robert et al.
N Engl J Med 2011

SL Topalian et al.
J Clin Oncol 2014

J Larkin et al.
N Engl J Med 2015

O Hamid et al.
N Engl J Med 2013

C Robert et al.
N Engl J Med 2015

JJ Luke et al.
Cancer 2013

L Zimmer et al.
PLoS One 2015

J Larkin et al.
Pigment Cell Melanoma Res 2016

L Min et al.
Cancer Immunol Res 2014

PA Prieto et al.
Clin Cancer Res 2012

Similar Publications